Arvinas (NASDAQ:ARVN) Trading 6.8% Higher

Arvinas, Inc. (NASDAQ:ARVN)’s stock price rose 6.8% during trading on Tuesday . The stock traded as high as $34.60 and last traded at $34.45. Approximately 359,949 shares traded hands during mid-day trading, a decline of 50% from the average daily volume of 717,537 shares. The stock had previously closed at $32.26.

Analyst Ratings Changes

A number of research firms have recently commented on ARVN. Barclays lifted their target price on Arvinas from $26.00 to $60.00 and gave the stock an “overweight” rating in a research note on Thursday, February 29th. The Goldman Sachs Group started coverage on shares of Arvinas in a report on Thursday, February 1st. They issued a “buy” rating and a $70.00 price target on the stock. Wedbush boosted their target price on Arvinas from $33.00 to $59.00 and gave the company an “outperform” rating in a research note on Wednesday, February 28th. Leerink Partnrs reiterated an “outperform” rating on shares of Arvinas in a research note on Thursday, February 22nd. Finally, HC Wainwright lowered their price objective on Arvinas from $90.00 to $87.00 and set a “buy” rating on the stock in a research note on Friday, April 12th. Two investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $59.73.

Arvinas Stock Performance

The stock’s 50 day simple moving average is $39.55 and its 200 day simple moving average is $35.44. The firm has a market cap of $2.35 billion, a PE ratio of -5.30 and a beta of 1.95.

Arvinas (NASDAQ:ARVN) last released its earnings results on Tuesday, February 27th. The company reported ($2.53) EPS for the quarter, missing analysts’ consensus estimates of ($1.15) by ($1.38). Arvinas had a negative net margin of 185.09% and a negative return on equity of 70.24%. The firm had revenue of ($43.10) million during the quarter, compared to the consensus estimate of $38.91 million. During the same period in the prior year, the company earned ($1.56) EPS. As a group, analysts anticipate that Arvinas, Inc. will post -5.02 earnings per share for the current year.

Insider Buying and Selling at Arvinas

In other Arvinas news, CFO Sean A. Cassidy sold 1,702 shares of the company’s stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $47.05, for a total transaction of $80,079.10. Following the completion of the sale, the chief financial officer now directly owns 181,916 shares in the company, valued at $8,559,147.80. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In related news, CFO Sean A. Cassidy sold 1,702 shares of Arvinas stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $47.05, for a total value of $80,079.10. Following the transaction, the chief financial officer now directly owns 181,916 shares of the company’s stock, valued at $8,559,147.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Ronald Peck sold 1,699 shares of the business’s stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $47.05, for a total transaction of $79,937.95. Following the completion of the transaction, the insider now owns 67,516 shares in the company, valued at approximately $3,176,627.80. The disclosure for this sale can be found here. Insiders have sold 8,597 shares of company stock worth $404,489 over the last ninety days. Insiders own 5.23% of the company’s stock.

Institutional Investors Weigh In On Arvinas

Large investors have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. boosted its position in Arvinas by 96.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,374 shares of the company’s stock valued at $27,000 after acquiring an additional 674 shares in the last quarter. BluePath Capital Management LLC bought a new position in Arvinas in the third quarter worth $28,000. BI Asset Management Fondsmaeglerselskab A S purchased a new position in Arvinas during the first quarter valued at $44,000. McGlone Suttner Wealth Management Inc. bought a new stake in shares of Arvinas during the 4th quarter valued at $75,000. Finally, Headlands Technologies LLC grew its holdings in Arvinas by 393.4% in the fourth quarter. Headlands Technologies LLC now owns 2,388 shares of the company’s stock worth $98,000 after purchasing an additional 1,904 shares during the period. Institutional investors own 95.19% of the company’s stock.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.